IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG).

Mouraux, André;Bloms-Funke, Petra;Boesl, Irmgard;Caspani, Ombretta;Treede, Rolf-Detlef;et.al.
(2021) Trials — Vol. 22, n° 1, p. 404 (2021)

Files

13063_2021_Article_5272.pdf
  • Open Access
  • Adobe PDF
  • 1.42 MB
Download

Details

Authors
  • Mouraux, Andréorcid-logoUCLouvain
    Author
  • Bloms-Funke, Petra
    Author
  • Boesl, Irmgard
    Author
  • Caspani, Ombretta
    Author
  • Stouffs, AlexandreUCLouvain
    Author
  • Treede, Rolf-Detlef
    Author
Show more
Abstract
IMI2-PainCare-BioPain-RCT3 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics, by providing a quantitative understanding between drug exposure and effects of the drug on nociceptive signal processing in human volunteers. IMI2-PainCare-BioPain-RCT3 will focus on biomarkers derived from non-invasive electroencephalographic (EEG) measures of brain activity. This is a multisite single-dose, double-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD) and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from scalp EEG measurements (laser-evoked brain potentials [LEPs], pinprick-evoked brain potentials [PEPs], resting EEG) will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose in separate study periods. Medication effects will be assessed concurrently in a non-sensitized normal condition and a clinically relevant hyperalgesic condition (high-frequency electrical stimulation of the skin). Patient-reported outcomes will also be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split between LEP and PEP under tapentadol. Remaining treatment arm effects on LEP or PEP or effects on EEG are key secondary confirmatory analyses. Complex statistical analyses and PK-PD modeling are exploratory. LEPs and PEPs are brain responses related to the selective activation of thermonociceptors and mechanonociceptors. Their amplitudes are dependent on the responsiveness of these nociceptors and the state of the pathways relaying nociceptive input at the level of the spinal cord and brain. The magnitude of resting EEG oscillations is sensitive to changes in brain network function, and some modulations of oscillation magnitude can relate to perceived pain intensity, variations in vigilance, and attentional states. These oscillations can also be affected by analgesic drugs acting on the central nervous system. For these reasons, IMI2-PainCare-BioPain-RCT3 hypothesizes that EEG-derived measures can serve as biomarkers of target engagement of analgesic drugs for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification. This trial was registered 25/06/2019 in EudraCT ( 2019%2D%2D001204-37 ).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Mouraux, A., Bloms-Funke, P., Boesl, I., Caspani, O., Chapman, S. C., Di Stefano, G., Finnerup, N. B., Garcia-Larrea, L., Goetz, M., Kostenko, A., Pelz, B., Pogatzki-Zahn, E., Schubart, K., Stouffs, A., Truini, A., Tracey, I., Troconiz, I. F., Van Niel, J., Vela, J. M., et al. (2021). IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG). Trials, 22(1), 404. https://doi.org/10.1186/s13063-021-05272-y (Original work published 2021)